- Home
- CCEL vs ADVM Comparison
CCEL vs ADVM Comparison
Compare CCEL & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEL
- ADVM
- Stock Information
- Founded
- CCEL 1989
- ADVM 2006
- Country
- CCEL United States
- ADVM United States
- Employees
- CCEL N/A
- ADVM N/A
- Industry
- CCEL Managed Health Care
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CCEL Health Care
- ADVM Health Care
- Exchange
- CCEL Nasdaq
- ADVM Nasdaq
- Market Cap
- CCEL 51.9M
- ADVM 59.5M
- IPO Year
- CCEL 1997
- ADVM 2014
- Fundamental
- Price
- CCEL $5.12
- ADVM $2.22
- Analyst Decision
- CCEL Strong Buy
- ADVM Strong Buy
- Analyst Count
- CCEL 1
- ADVM 5
- Target Price
- CCEL $8.50
- ADVM $26.40
- AVG Volume (30 Days)
- CCEL 10.1K
- ADVM 430.7K
- Earning Date
- CCEL 07-14-2025
- ADVM 05-14-2025
- Dividend Yield
- CCEL 7.81%
- ADVM N/A
- EPS Growth
- CCEL N/A
- ADVM N/A
- EPS
- CCEL 0.01
- ADVM N/A
- Revenue
- CCEL $32,102,750.00
- ADVM $1,000,000.00
- Revenue This Year
- CCEL $2.49
- ADVM N/A
- Revenue Next Year
- CCEL $0.95
- ADVM $42.58
- P/E Ratio
- CCEL $321.51
- ADVM N/A
- Revenue Growth
- CCEL 2.33
- ADVM N/A
- 52 Week Low
- CCEL $4.75
- ADVM $1.78
- 52 Week High
- CCEL $9.43
- ADVM $10.14
- Technical
- Relative Strength Index (RSI)
- CCEL 48.65
- ADVM 36.90
- Support Level
- CCEL $4.79
- ADVM $2.10
- Resistance Level
- CCEL $5.15
- ADVM $2.33
- Average True Range (ATR)
- CCEL 0.17
- ADVM 0.24
- MACD
- CCEL 0.05
- ADVM 0.03
- Stochastic Oscillator
- CCEL 63.79
- ADVM 32.65
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.